Treatment algorithm for metastatic renal cell carcinoma - Recommendations based on evidence and clinical practice

Oncology Research and Treatment

Volumn 37, Issue 3, 2014, Pages 136-141

  Bergmann, Lothar ^a   Beck, Jochaim ^b   Bothe, Kathrin ^c   Brinkmann, Olaf A ^d   Buse, Stephan ^e   Goebell, Peter J ^f   Grünwald, Viktor ^g   Holzapfel, Konstantin ^h   Kübler, Hubert ^h   Marschner, Norbert W ⁱ   Mickisch, Gerald ^j   Schultze Seemann, Wolfgang ^k   Siebels, Michael ^l   Siemer, Stephan ^m   Störkel, Stephan ⁿ   Gschwend, Jürgen E ^h  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d ST BONIFATIUS HOSPITAL   (Germany)

^e ALFRIED KRUPP KRANKENHAUS   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^g Hamatologiem Hamostaseologie Onkologie und Stammzelltransplantation   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ Gemeinschaftspraxis für Interdisziplinäre Onkologie und Hämatologie   (Germany)

^j Centrum für Operative Urologie Bremen   (Germany)

^k UNIVERSITY OF FREIBURG   (Germany)

^l Gemeinschaftspraxis Urologie Pasing   (Germany)

^m SAARLAND UNIVERSITY   (Germany)

ⁿ Helios Clinics   (Germany)

more..

Author keywords

mRCC; mTOR; Renal cell cancer; Therapy sequences; TKI; VEGF

Indexed keywords

AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; MONOCLONAL ANTIBODY;

ALGORITHM; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; CLINICAL PRACTICE; DIARRHEA; ENZYME INHIBITION; EVIDENCE BASED PRACTICE; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; STOMATITIS; TUMOR GROWTH; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; MOLECULARLY TARGETED THERAPY; ONCOLOGY; SECONDARY; STANDARDS; TREATMENT OUTCOME;

ALGORITHMS; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84910132838     PISSN: 22965270     EISSN: 22965262     Source Type: Journal    
DOI: 10.1159/000360179     Document Type: Article

References (26)

1. Motzer RJ, Figlin RA, Hutson TE, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
2. Sternberg CN, Davis ID, Mardiak J, et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8.
3. Escudier B, Pluzanska A, Koralewski P, et al.: Bevacizumab plus interferon-Alfa2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
4. Hudes G, Carducci M, Tomczyk P, et al.: Temsirolimus, interferon, or both for advanced renal cell carcinoma. N Engl J Med 2007;336:2271-81.
5. Escudier B, Eisen T Stadler WM, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
6. Négrier S, Gravis G, Pérol D, et al.: Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORACA): a randomised phase II trial. Lancet Oncol 2011;12:673-80.
7. Motzer RJ, Escudier B, Oudard S, et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised placebo-controlled phase 3 trial. Lancet 2008;372:449-56.
8. Patard JJ. Leray E, Rioux-Leclercq N, et al.: Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23:2763-71.
9. Motzer RJ, Bacik J, Murphy B, et al.: Interferonalfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96.
10. Heng DY, Xie W, Regan MM, et al.: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-Targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27: 5794-9.
11. Kwon WA, Cho IC, Yu A, et al.: Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib. Ann Surg Oncol 2013;20:4397-404.
12. Manola J, Royston P, Elson P, et al.: Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the International Kidney Cancer Working Group. Clin Cancer Res 2011;17:5443-50.
13. Escudier B, Szyczylik C, Porta C, et al.: Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol 2012;9:327-37.
14. Melichar B, Koralewski P, Ravaud A, et al.: Firstline bevacizumab combined with reduced dose interferon alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008;8: 1470-76.
15. Melichar B. Bevacizumab (BEV) + low-dose interferon 2a (IFN) for first-line treatment of metastatic renal cell carcinoma (mRCC): final safety and efficacy data from the prospective BEVLiN study. ESMO 2012;abstr 809P.
16. Auswertung des Tumorregisters Nierenzellkarzinom, Stand September 2012, Registerdatenbank der iOMEDICO AG.
17. Motzer RJ, Hudson TE, Reeves J, et al.: Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal-cell carcinoma (mRCC): results of the COMPARZ trial. ESMO 2012;abstr LBA8.
18. Escudier B, Szcylik C, Hutson TE, et al.: Randomized phase II trial of first-line treatment of sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:1280-9.
19. Jonasch E, Corn P, Pagliaro LC, et al.: Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010;116:57-65.
20. Procopio G, Verzoni E, Bracarda S, et al.: Sorafenib with interleukin-2 vs. sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer 2011;104:1256-61.
21. Rini B, Wilding G, Hudes G, et al.: AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): a randomized, double-blind, placebo-controlled, phase II trial. J Clin Oncol 2011:29(suppl 7):abstr 309.
22. Hutson T, Escudier B, Esteban E, et al.: Temsirolimus vs sorafenib as second-line therapy in metastatuic renal cell carcinoma: results from the INTORSECT trial. ESMO 2012;abstr LBA22.
23. Motzer JR, Barrios CH, Kim TM, Falcon S, Cosgriff T, et al.: Record-3: phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013;Beilage 1 31. 15.
24. Rini BI, Escudier B, Tomczak P, et al.: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9.
25. Motzer RJ, Hutson TE, Olsen MR, et al.: Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal carcinoma: renal EFFECT trial. J Clin Oncol 2011;29(suppl 7):abstr LBA 308.
26. Rini BI, Halabi S, Rosenberg JE, et al.: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137-43.